Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Select optimal first-line immune checkpoint inhibitor and chemotherapy combinations for patients with advanced or metastatic NSCLC
Evaluate the available clinical data on biomarkers of response to immune checkpoint inhibitor–based therapy in NSCLC
Identify patients most likely to benefit from immunotherapy for unresectable stage III NSCLC following chemoradiation therapy and in those who are ineligible for surgery or chemoradiation therapy
Incorporate investigational checkpoint inhibitors and clinical trial participation as part of clinical care strategies for NSCLC
Address factors that have the potential to reduce efficacy of ICI therapy in individual patients with NSCLC
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Professor of Oncology
Director, Thoracic Oncology
Co-Director, Upper Aerodigestive Cancer Program
Bloomberg-Kimmel Institute for Cancer Immunology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Adjunct Assistant Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Senior Clinical Editor
Associate Director, Scientific Services
Senior Director, Educational Strategy
Director, CME Program Development
Associate Director, Educational Strategy
Director, Program Development and Educational Impact
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This educational program is intended for medical oncologists and other healthcare professionals who treat patients with non-small-cell lung cancer.
The goal of this program is to improve the knowledge and competence of learners in immuno-oncology for the treatment of non-small-cell lung cancer.
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 07, 2021, through October 06, 2022:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Watch this on-demand webcast of a live CCO webinar where lung cancer experts discuss the latest advances in immunotherapy for the management of NSCLC across the disease spectrum, including in special populations and new data from WCLC 2021.
In this commentary from Clinical Care Options (CCO), Dr. David Planchard provides an overview of the status of EGFR TKI combination therapy for newly diagnosed EGFR-mutated advanced NSCLC.
Downloadable slideset on the use of neoadjuvant immunotherapy in resectable early-stage lung cancer, from Clinical Care Options (CCO)
Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on EGFR Exon 20–Altered NSCLC.
PDF transcript of a podcast where lung cancer experts answer clinical questions on evolving immunotherapy strategies for NSCLC, from Clinical Care Options (CCO)